## Na L

Position: Associate Professor



Faculty: State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and

Health, Macau University of Science and Technology

Email: nli@must.edu.mo Telephone: (853) 8897-2405 Fax No.: (853) 2882-5886

Office: H833-02


Mailing Avenida Wai Long, Taipa, Macau

Address: Macau University of Science and Technology

T ac : Chinese Medicine Chemistry (BP12209/BPAZ0010), Unique Processing Methods of Chinese Medicines (BP12307), Experimental Techniques in Natural Products Chemistry Research (ME 1008), Advances in Chinese Medicine Pharmaceutics (DCMSZ01/ME1005)

**R** a c a a : Natural product chemistry and Chinese herbal toxicology

Dr. Na Li obtained her Ph.D. degree in Medicinal Chemistry from China Pharmaceutical University in 1999. She proceeded to her postdoctorial training at Institute of Materia Medica of Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC) during 1999-2001. In 2001, she was sponsored by Japan Society for the Promotion of Science (JSPS) to work as a postdoctoral research fellow in Niigata University, Japan. From 2003 to 2007, she engaged in the study of bioactive compounds in The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS). Her research in The Chinese University of Hong Kong during the period 2007 to 2011 mainly focused on the toxicity of natural products. She works as a principal investigator in Macau University of Science and Technology (MUST) from 2011, and the research interests include the method development and application of proteomics to reveal the mechanism of Chinese herbal medicines as well as the identification of bioactive natural products. She has rich experience in the research of natural



## Academic Qualifications

1999.7 Ph. D. China Pharmaceutical University, Nanjing, Jiangsu Province, China

1994.7 B. Sc. West China University of Medical Sciences, Chengdu, Sichuan Province

China

## Working Experiences

2018.7 - Present Associate Profess

Medicine, Macau University of Science and Technologh

- WY Gu, MX Liu, I Sun, MQ Lo, JL N L\*. Fining of polyunsaturated fatty acids in human so in using line are in line phase extraction-nano-liquid chromatography-quadrupole-time-of-flight mass spectrometry. *J Chromatogr A* **2018**, *1537*, 141-146.
- 5) Y Zhuo, JL Wu, XJ Yan, MQ Guo, N Liu, H Zhou, L Liu\*, N L \*. Strategy for Hepatotoxicity Prediction Induced by Drug Reactive Metabolites Using Human Liver Microsome and Online 2D-nano-LC-MS Analysis. *Anal Chem* **2017**, *89*, 13167-13175.
- 6) XQ Bian, Ballossūn, PY Zheng, N L\*, JL Wu\*. Derivatization enhanced separation and sensitivity of long chain-free fatty acids: Application to asthma using targeted and non-targeted liquid chromatography-mass x, v Y

- alkaloids from Lycoris radiata targeting DNA topoisomerase I. Sci. Rep. 2016, 6, 38284.
- 15) JJ Wu, N Lin, FY Li, GY Zhang, SG He, YF Zhu, RL Qu, N L, SQ Liu, LZ Feng, L Liu, ZQ Liu, LL Lu. Induction of P-glycoprotein expression and activity by Aconitum alkaloids: implication for clinical drug-drug interactions. *Sci. Rep.* **2016**, *6*, 25343.
- 16) L Zhu, JQ Ruan, N L, PP Fu, Y Ye, G Lin. A novel ultra-performance liquid chromatography hyphenated with quadrupole time of flight mass spectrometry method for rapid estimation of total toxic retronecine-type of pyrrolizidine alkaloids in herbs without requiring corresponding standards. *Food Chem.* **2016**, *194*, 1320-1328.
- 17) ZB Jiang, J Huang, C Xie, X Li, L Liu, J He, H Pan, L Huang, XX Fan, XJ Yao, Y Xie, N L, L Liu, JX He, EL Leung. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations. *Oncol. Rep.* **2016**, *36(1)*, 365-375.
- 18) J Ruan, H Gao, N L, J Xue, J Chen, C Ke, Y Ye, PP Fu, J Zheng, J Wang, G Lin. Blood pyrrole-protein adducts A biomarker of pyrrolizidine alkaloid-induced liver injury in humans. *J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev.* **2015**, *33*, 404-421.
- 19) YH Li, WCS Tai, JY Xue, WY Wong, C Lu, JQ Ruan, N L, TF Wan, WY Chan, WLW Hsiao, and G Lin. Proteomic Study of Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome in Rats. *Chem. Res. Toxicol.* **2015**, *28*, 1715-1727.
- 20) H Gao, JQ Ruan, J Chen, N L, CQ Ke, Y Ye, G Lin, JY Wang. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome. *Drug Design, Development and Therapy* **2015**, *9*, 4861-4868.
- 21) WY Gu, N L\*, ELH Leung, H Zhou, XJ Yao, L Liu, JL Wu\*. Rapid identification of new minor chemical constituents from Smilacis Glabrae Rhizoma by combined use of UHPLC-Q-TOF-MS, preparative HPLC and UHPLC-SPE-NMR-MS techniques. *Phytochem. Anal.* 2015, 26, 428-435.
- 22) WY Gu, **N** L\*, ELH Leung, H Zhou, GA Luo, L Liu, JL Wu\*. Metabolites software-assisted flavonoids hunting in plant using ultra-high performance liquid chromatography-quadrupole-time of flight mass spectrometry. *Molecules* **2015**, *20*, 3955-3971.
- 23) L Zhu, N L, JQ Ruan, PP Fu, ZZ Zhao, G Lin. Chemical diversity investigation of hepatotoxic pyrrolizidine alkaloids in Qianliguang (*Senecio scandens*) and related species by UHPLC-QTOF-MS. World J. Tradit. Chin. Med. 2015, 1, 1-11.
- 24) XX Fan, N L, et al. Celastrol induces apoptosis in gefitinib-resistant non-small cell lung cancer cells via caspases-dependent pathways and Hsp90 client protein degradation.

- Molecules 2014, 19, 3508-3522.
- 25) JL Wu, EL Leung, H Zhou, L Liu\*, **N** L\*. Metabolite analysis of toosendanin by an ultrahigh performance liquid chromatography-quadrupole-time of flight mass spectrometry technique. *Molecules* **2013**, *18*, 12144-12153.
- 26) YH Li, WL Kan, **N** L, G Lin. Assessment of pyrrolizidine alkaloid-induced toxicity in an in vitro screening model. *J. Ethnopharmacol.* **2013**, *150*, 560-567.
- 27) J Ruan, **N** L, et al. Characteristic ion clusters as determinants for the identification of pyrrolizidine alkaloid *N*-oxides in pyrrolizidine alkaloid–containing natural products using HPLC–MS analysis. *J. Mass Spectrom.* **2012**, *47*, 331-337.
- 28) Q Liu, **N** L, et al. Cyclobutane derivatives as novel nonpeptidic small molecule agonists of glucagon-like peptide-1 receptor. *J. Med. Chem.* **2012**, *55*(1), 250-267.
- 29) H Gao, **N** L, et al. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids. *J. Dig. Dis.* **2012**, *13*, 33-39.
- 30) B Ma, S Chai, **N** L, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a synthetic α-aminoxy peptidomimetic. *Int. J. Pharm.* **2012**, *424*, 33-39.
- 31) B Ma, N L, G Lin. Importance of Metabolic Activation Study to the Safe Use of Chinese Herbal Medicines. *Curr. Drug Metab.* **2012**, *13*, 652-658.
- 32) G Lin,\* JY Wang,\* N L, et al. Hepatic sinusoidal obstruction syndrome associated with consumption of *Gynura segetum*. *J. Hepatol.* **2011**, *54*, 666-673.
- 33) B Ma, HY Zha, N L, et al. Effect of structural modification of α-aminoxy peptides on their intestinal absorption and transport mechanism. *Mol. Pharmaceutics* **2011**, *8*, 1073-1082.
- 34) **N** L, Q Xia, J Ruan, et al. Hepatotoxicity and tumorigenicity induced by metabolic activation of pyrrolizidine alkaloids in herbs. *Curr. Drug Metab.* **2011**, *12*, 823-834.